Full Papers
Cardiovascular risk management in gout patients: do patients benefit from screening in secondary care?
D. Vedder1, M. Heslinga2, C.A. Wijbrandts3, M.T. Nurmohamed4, M. Gerritsen5
- Amsterdam Rheumatology and Immunology Center Reade, Amsterdam; and Vrije Universiteit, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands. d.vedder@reade.nl
- Amsterdam Rheumatology and Immunology Center Reade, Amsterdam; and Vrije Universiteit, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
- Amsterdam Rheumatology and Immunology Center Reade, Amsterdam, The Netherlands.
- Amsterdam Rheumatology and Immunology Center Reade, Amsterdam; Vrije Universiteit, Amsterdam Cardiovascular Sciences, Amsterdam; and Department of Rheumatology, Amsterdam UMC, Amsterdam, The Netherlands.
- Amsterdam Rheumatology and Immunology Center Reade, Amsterdam, The Netherlands.
CER16136
2023 Vol.41, N°9
PI 1762, PF 1767
Full Papers
PMID: 37279144 [PubMed]
Received: 15/08/2022
Accepted : 07/12/2022
In Press: 06/06/2023
Published: 17/08/2023
Abstract
OBJECTIVES:
To estimate the 10-year cardiovascular disease (CVD) risk in gout patients in secondary care and to evaluate the effect of CVD risk screening on the 10-year CVD risk after 1 year.
METHODS:
A prospective cohort study was performed in patients with gout from Reade Amsterdam. Data on gout and CVD history, traditional risk factors, medication, and lifestyle were collected at baseline and 1 year. The 10-year CVD risk was calculated with the use of the NL-SCORE. A paired sample t-test and McNemar test was performed to test for differences between baseline and the 1-year visit.
RESULTS:
A very high prevalence of traditional CV risk factors was seen in our secondary care gout patients. Nineteen percent without previous CVD were categorised in the high-risk group according the NL-SCORE. The prevalence of CVD increased from 16% to 21% after 1-year follow-up. A decrease was seen in total- and LDL-cholesterol after 1 year. No decrease in mean BMI, waist-hip ratio, blood pressure or NL-SCORE was observed.
CONCLUSIONS:
The current need for CVD risk screening of gout patients in secondary care was illustrated by the high prevalence of traditional risk factors in this cohort. Recommendations to patients and the general practitioner (GP) alone did not result in overall improvement of traditional CVD risk factors nor the 10-year CVD risk. Our results indicate that a more prominent role of the rheumatologist is necessary to optimise the process of initiation and management of CVD risk in gout patients.
